je.st
news
Tag: world
Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
2016-12-06 14:20:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Microgrids in a Customer Choice World
2016-12-05 22:39:00| Transmission & Distribution World
Hannah Moulthrop Moving to Platforms Chicago utility experiments with new ways to touch customers read more
Tags: world
customer
choice
microgrids
K&N Helps Make Aston Martin Racing GTE World Endurance Championship Possible
2016-12-02 17:26:04| K&N Racing News
The Aston Martin factory team won the World Endurance Champions (WEC) in the GTE Pro Division (the highest level just below prototypes) in their highly-modified Aston Martin GTE race cars. The championship battle with the AF Corse Ferrari had come down to the final race in Bahrain, but Aston vanquished its foe.
Tags: make
world
possible
martin
New KEYTRUDA (pembrolizumab) Data to be Presented at 17th World Conference on Lung Cancer Highlight Research Across the Spectrum of Thoracic Malignancies
2016-11-30 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings to be Presented in Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Malignant Pleural Mesothelioma with KEYTRUDA as Monotherapy and in Combination with Other Treatments Quality of Life Data from KEYNOTE-024 in First-Line Non-Small Cell Lung Cancer to be Presented in Plenary Session KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. Language: English Contact: Media Contacts:Pamela Eisele, (267) 305-3558orKim Hamilton, (908) 740-1863orInvestor Contacts:Teri Loxam, (908) 740-1986orAmy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Lenzing world leader for sustainable wood sourcing
2016-11-30 12:18:00| Daily apparel & textile news and comment - from just-style.com
Austrian cellulosic fibre producer Lenzing has been rated number one globally with respect to the procurement of wood, the key raw material in cellulose fibre production.
Tags: world
wood
leader
sustainable
Sites : [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] next »